In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or maybe the members are not able to tolerate the study drugs. - Participant eaten grapefruit or grapefruit goods within three times before https://franko787bmw9.wikififfi.com/user